Breast cancer prognosis and management for both men and women are reliant upon
estrogen receptor alpha (ERα) and progesterone receptor (PR) expression to inform …

Male breast cancer remains understudied despite evidence of rising incidence. Using a co-
ordinated multi-centre approach, we present the first large scale biomarker study to define …

Introduction Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in
the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to …

PURPOSE: Hormone receptor expression (presence-positive or absence-negative) may
reflect different stages of one disease or different breast cancer types. Determining whether …

Estrogen signaling plays an essential role in breast cancer progression, and estrogen
receptor (ER) status has long been a marker of hormone responsiveness. However, ER …

Male breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical
management is based on results obtained from randomized trials conducted in women …

Breast cancer subtypes defined by estrogen receptor (ER), progesterone receptor (PR), and
HER2 expression are biologically distinct and thus, may have distinct etiologies. In …

Background Breast cancer (BC) has the highest cancer incidence and mortality in women
worldwide. Observational epidemiological studies suggest a positive association between …

Background Although several transcriptome-wide association studies (TWASs) have been
performed to identify genes associated with overall breast cancer (BC) risk, only a few TWAS …

Purpose Androgen receptor (AR) expression is absent in 40–90% of estrogen receptor (ER)-
negative breast cancers. The prognostic value of AR in ER-negative patients and …